<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) represent a diverse set of diseases, with different treatment pathways based on the stage and type of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In their presentation at the <z:chebi fb="0" ids="29308,30347">NCCN</z:chebi> 18th Annual Conference, Dr. Jeremy Abramson and Dr. Andrew D </plain></SENT>
<SENT sid="2" pm="."><plain>Zelenetz discuss 3 specific B-cell NHLs: follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>They provided an overview of the treatment strategies for patients with these <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, and offered highlights from recent clinical trials supporting these recommendations </plain></SENT>
</text></document>